dc.contributor.author |
Andreopoulos, AG |
en |
dc.contributor.author |
Korakis, T |
en |
dc.contributor.author |
Dounis, E |
en |
dc.contributor.author |
Anastasiadis, A |
en |
dc.contributor.author |
Tzivelekis, P |
en |
dc.contributor.author |
Kanellakopoulou, K |
en |
dc.date.accessioned |
2014-03-01T01:11:59Z |
|
dc.date.available |
2014-03-01T01:11:59Z |
|
dc.date.issued |
1996 |
en |
dc.identifier.issn |
0885-3282 |
en |
dc.identifier.uri |
https://dspace.lib.ntua.gr/xmlui/handle/123456789/11912 |
|
dc.relation.uri |
http://www.scopus.com/inward/record.url?eid=2-s2.0-0030111847&partnerID=40&md5=314ebefc9fc7a87c3ad6e406f66c3bd9 |
en |
dc.subject |
Biodegradable polymers |
en |
dc.subject |
Ciprofioxacin |
en |
dc.subject |
Drug delivery systems |
en |
dc.subject |
New quinolones |
en |
dc.subject |
Ofloxacin |
en |
dc.subject.classification |
Engineering, Biomedical |
en |
dc.subject.classification |
Materials Science, Biomaterials |
en |
dc.subject.other |
Antibiotics |
en |
dc.subject.other |
Bacteria |
en |
dc.subject.other |
Biodegradation |
en |
dc.subject.other |
Bone |
en |
dc.subject.other |
Diseases |
en |
dc.subject.other |
Molecular weight |
en |
dc.subject.other |
Organic compounds |
en |
dc.subject.other |
Organic polymers |
en |
dc.subject.other |
Ciprofloxacin |
en |
dc.subject.other |
Minimum inhibitory concentration |
en |
dc.subject.other |
Ofloxacin |
en |
dc.subject.other |
Osteomyelitis |
en |
dc.subject.other |
Polylactic acid |
en |
dc.subject.other |
Quinolones |
en |
dc.subject.other |
Controlled drug delivery |
en |
dc.subject.other |
antiinfective agent |
en |
dc.subject.other |
ciprofloxacin |
en |
dc.subject.other |
drug carrier |
en |
dc.subject.other |
lactic acid |
en |
dc.subject.other |
ofloxacin |
en |
dc.subject.other |
polylactic acid |
en |
dc.subject.other |
polymer |
en |
dc.subject.other |
article |
en |
dc.subject.other |
bioremediation |
en |
dc.subject.other |
chemistry |
en |
dc.subject.other |
comparative study |
en |
dc.subject.other |
culture medium |
en |
dc.subject.other |
delayed release formulation |
en |
dc.subject.other |
diffusion |
en |
dc.subject.other |
drug delivery system |
en |
dc.subject.other |
in vitro study |
en |
dc.subject.other |
molecular weight |
en |
dc.subject.other |
statistics |
en |
dc.subject.other |
time |
en |
dc.subject.other |
Anti-Infective Agents |
en |
dc.subject.other |
Biodegradation, Environmental |
en |
dc.subject.other |
Ciprofloxacin |
en |
dc.subject.other |
Culture Media |
en |
dc.subject.other |
Delayed-Action Preparations |
en |
dc.subject.other |
Diffusion |
en |
dc.subject.other |
Drug Carriers |
en |
dc.subject.other |
Drug Delivery Systems |
en |
dc.subject.other |
Lactic Acid |
en |
dc.subject.other |
Molecular Weight |
en |
dc.subject.other |
Ofloxacin |
en |
dc.subject.other |
Polymers |
en |
dc.subject.other |
Time Factors |
en |
dc.title |
In vitro release of new quinolones from biodegradable systems: A comparative study |
en |
heal.type |
journalArticle |
en |
heal.language |
English |
en |
heal.publicationDate |
1996 |
en |
heal.abstract |
A new biodegradable delivery system based on low molecular weight poly(lactic acid) has been formualted, with potential application in the sustained antibiotic release against bone infection. The in vitro release of two new quinolones (ofloxacin and ciproftoxacin) from the biodegradable matrix showed that the delivery of ofloxacin from the matrix lasted fifty-six days, whereas that of ciprofloxacin lasted fifty-one days. In both cases, release is controlled by the drug diffusion and the matrix degradation, the latter being the most critical factor. The obtained concentration levels are well above the Minimum Inhibitory Concentration (MIC) against the major causative bacteria of osteomyelitis. This fact in combination with the good reproducibility of measurements indicated that the system studied could be of value for the preparation of implantable controlled release systems for treatment of diseases in the bone system. |
en |
heal.publisher |
TECHNOMIC PUBL CO INC |
en |
heal.journalName |
Journal of Biomaterials Applications |
en |
dc.identifier.isi |
ISI:A1996UH63800003 |
en |
dc.identifier.volume |
10 |
en |
dc.identifier.issue |
4 |
en |
dc.identifier.spage |
338 |
en |
dc.identifier.epage |
347 |
en |